Clinical Trials Logo

Clinical Trial Summary

Chronic rhinosinusitis (CRS) with (w) and without (s) nasal polyps (NP) in its different shapes is currently affecting up to 16% of the total population of the United States and around 11% of the population in Europe. It may also be associated with a hypersensitivity to non-steroidal anti-inflammatory (NSAID) drugs in a syndrome called NSAID-exacerbated respiratory disease (N-ERD) characterized by highly recurrent polyps and concomitant asthma. The pathophysiological mechanisms especially with regards to the potential role of the microbiome in driving N-ERD are so far not fully understood. Here, the investigators plan to analyse the nasal microbiome in these patients and to compare it to nasal samples from CRSwNP and CRSsNP patients as well as healthy controls (in total 80 subjects). This will provide insights into potential differences in the microbiome as compared to other CRS patients and the impact of the microbiome in driving this disease.


Clinical Trial Description

Chronic rhinosinusitis (CRS) with (w) and without (s) nasal polyps (NP) in its different shapes is currently affecting up to 16% of the total population of the United States and around 11% of the population in Europe . However CRS may also be associated with hypersensitivity to aspirin and other non-selective cyclooxygenase inhibitors. This syndrome of combined CRSwNP, asthma and intolerance to inhibitors of the cyclooxygenase-1 enzyme was termed Samter's triad, aspirin-exacerbated respiratory disease (AERD) and recently NSAID-exacerbated respiratory disease (N-ERD). N-ERD is thought to affect around 16% of patients suffering from CRSwNP , around 7% of adult asthmatic patients and 0.3-2.5% of the general population. One characteristic feature of this disease is the presence of nasal polyps that frequently relapse after surgery rendering this disease difficult to manage. Despite its relatively high prevalence, the pathophysiologic mechanisms are yet not fully understood. In this respect, an overproduction of and overresponsiveness to cysteinyl leukotrienes accompanied by and underproduction of and underresponsiveness to prostaglandins was observed in N-ERD patients.This indicates a dysregulation of pro and anti-inflammatory pathways. Our mucosal body surfaces are colonized by a large variety of microbes organized within complex community structures. Novel sequencing techniques (e.g. 16SrRNA sequencing) have facilitated in-depth analysis of the nasal microbiome in health and disease. Recent studies show amongst other an enrichment in Haemophilus and Streptococcus in the nose of CRS patients, whereas nasal microbiome of healthy patients is rich in Propionibacterium acnes . So far, differences in microbiome were observed in healthy versus CRS patients, but the impact of the microbial environment in N-ERD has not been assessed yet and is thus aim of the study. The investigators will collect nasal microbiome and nasal secretions from patients suffering from N-ERD and will compare them to the microbiome of CRSwNP, CRSsNP and healthy controls (n=20 per group). Additionally, cytokines in nasal secretions, protein expression at mRNA levels in nasal mucosa, and serum of these patients and clinical parameters (e.g. total nasal polyp score, quality of life questionnaire, olfactory performance) will be determined. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04375293
Study type Interventional
Source Medical University of Vienna
Contact
Status Completed
Phase N/A
Start date January 7, 2020
Completion date July 25, 2021

See also
  Status Clinical Trial Phase
Terminated NCT05331222 - Proof-of-Concept Interventional Study With a Nasal Spray of JT-1 in Patients With Chronic Rhinitis or Chronic Sinusitis N/A
Active, not recruiting NCT05591989 - Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON) N/A
Active, not recruiting NCT04614324 - A Study of RhinAer ARC Stylus for Treating Chronic Rhinitis (RELIEF) N/A
Recruiting NCT01546662 - A Randomized Double Dummy Double Blind Dose Determining Place-bo Controlled Study to Evaluate Efficacy of Investigational Product E-RH-06 at 2 Dose Levels for the Metabolic Management of Chronic or Recurrent, Non-infective Nasal Congestion With-or-without Rhinorrhea. N/A
Terminated NCT00737906 - Surgical Reduction of the Inferior Turbinates for Nasal Obstruction Phase 4
Completed NCT03727347 - Posterior Nasal Nerve (PNN) Rhinitis Study N/A
Recruiting NCT06128200 - NEUROMARK Randomized Controlled Trial N/A
Active, not recruiting NCT04154605 - ClariFix Rhinitis RCT N/A
Recruiting NCT05626621 - Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis Phase 4
Completed NCT04684875 - Quality of Life Impact of Chronic Rhinitis Treatment With Aerin Medical Device
Completed NCT01364467 - The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study Phase 2
Completed NCT03181594 - Evaluation of the ClariFix™ Cryotherapy Device in Subjects With Chronic Rhinitis N/A
Completed NCT05324397 - Safety and Efficacy Study of the Neurent Medical NEUROMARK™ System in Subjects With Chronic Rhinitis (CLARITY) N/A
Completed NCT03739216 - Registry of Subject Treated With ClariFix
Recruiting NCT05937308 - NEUROMARK Registry Study N/A
Active, not recruiting NCT04533438 - RhinAer Procedure for Treatment of Chronic Rhinitis Study N/A
Completed NCT03893227 - Prevalence of Nasal Hyperreactivity in Chronic Upper Airway Inflammation
Terminated NCT00584662 - Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion N/A
Recruiting NCT05648565 - Effects of Radiofrequency Ablation of Posterior Nasal Nerves on Inflammatory Cytokines, Peak Nasal Inspiratory Flow, and Nasal Blood Flow in Patients With Chronic Rhinitis N/A
Completed NCT04769596 - Safety and Efficacy Study of the Neurent Medical NEUROMARK™ System in Subjects With Chronic Rhinitis N/A